Abstract:In this work, a microenvironmentally dual‐responsive nano‐drug, TSD@LSN‐D, for prostate cancer self‐synergistic immunotherapy is developed. Within tumor cells, decitabine assists the occurrence of immunogenic pyroptosis after PDT. The powerful immunomodulatory effects triggered by TSD@LSN‐D not only stimulate a solid anti‐tumor immune response to suppress the primary tumor, but also create a long‐term immune memory to prevent tumor recurrence and metastasis. Induction of immunogenic cell death (ICD) in tumor combined with immune checkpoint blockade (ICB) therapy is widely developed to improve the efficacy of cancer immunotherapy. However, the current ICD induced based on apoptosis, i.e., immunogenic apoptosis, is often restricted in immunogenicity owing to the inflammatory quenching that occurs early in apoptosis. Recently, pyroptosis is demonstrated to be a more efficient ICD form, i.e., immunogenic pyroptosis. The cell contents released during pyroptosis can powerfully activate tumor immunogenicity. Herein, first, it is demonstrated that lower doses of epigenetic drug decitabine can increase GSDME expression in prostate cancer (PCa) RM‐1 cells and successfully induce an apoptosis‐pyroptosis transition after photodynamic therapy (PDT). Subsequently, a microenvironment dual‐responsive nano‐drug equipped with PD‐L1 blocking peptide (TSD@LSN‐D) is developed for self‐synergistic cancer immunotherapy. The poorly immunogenic RM‐1 PCa model confirm that the powerful antitumor immune response evoked by TSD@LSN‐D not only can effectively inhibit the primary tumor but also form a long‐term immune memory to prevent PCa recurrence and metastasis. To the best of authors' knowledge, this work presents the first concept that promotes the apoptosis–pyroptosis transition after tumor PDT through epigenetic modulation. Furthermore, the powerful combination of immunogenic pyroptosis with ICB opens a new platform for PCa immunotherapy.

Photoimmunotherapy-Induced Pyroptosis Remodels the Microenvironment to Enhance Cancer Immunotherapy

Nanoagonist‐Mediated GSDME‐Dependent Pyroptosis Remodels the Inflammatory Microenvironment for Tumor Photoimmunotherapy

Simultaneous Activation of Pyroptosis and cGAS‐STING Pathway with Epigenetic/ Photodynamic Nanotheranostic for Enhanced Tumor Photoimmunotherapy

Cancer immunogenic cell death via photo-pyroptosis with light-sensitive Indoleamine 2,3-dioxygenase inhibitor conjugate

Pyroptosis Remodeling Tumor Microenvironment to Enhance Pancreatic Cancer Immunotherapy Driven by Membrane Anchoring Photosensitizer

Biomimetic Nano‐Photosensitizer Amplifies Immunogenic Pyroptosis and Triggers Synergistic Cancer Therapy

Inspired heat shock protein alleviating prodrug enforces immunogenic photodynamic therapy by eliciting pyroptosis

Synergistically Augmenting Cancer Immunotherapy by Physical Manipulation of Pyroptosis Induction

Photodynamic Modulation of Endoplasmic Reticulum and Mitochondria Network Boosted Cancer Immunotherapy

Pyroptosis of Breast Cancer Stem Cells and Immune Activation Enabled by a Multifunctional Prodrug Photosensitizer

Eliciting pyroptosis to fuel cancer immunotherapy: mechanisms and strategies

Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief

A Microenvironment Dual‐Responsive Nano‐Drug Equipped with PD‐L1 Blocking Peptide Triggers Immunogenic Pyroptosis for Prostate Cancer Self‐Synergistic Immunotherapy

Recent strategies for evoking immunogenic Pyroptosis in antitumor immunotherapy

PhotoPyro‐induced cGAS‐STING Pathway Activation Enhanced Anti‐Melanoma Immunotherapy via a Manganese‐Coordinated Nanomedicine

Enhancing tumor immunotherapy via photodynamic therapy with a cascade reaction of reactive oxygen species and sustaining nutrient supply

Phototherapy and anti-GITR antibody-based therapy synergistically reinvigorate immunogenic cell death and reject established cancers

A Mild Hyperthermia Hollow Carbon Nanozyme as Pyroptosis Inducer for Boosted Antitumor Immunity

Photon‐driven dye induction pyroptosis: An emerging anti‐tumor immunotherapy paradigm

Hypoxia-accelerating pyroptosis nanoinducers for promoting image-guided cancer immunotherapy

Golgi Apparatus-Targeted Photodynamic Therapy for Enhancing Tumor Immunogenicity by Eliciting NLRP3 Protein-Dependent Pyroptosis